Nursing of the patients with HER2-positive advanced gastric cancer who were treated with trastuzumab combination with modified DCF regimen chemotherapy

Abstract

Objective To summarize experience of nursing the patients with human epidermal growth factor receptor 2 (HER-2)-positive advanced gastric cancer who were treated with trastuzumab combination with modified DCF regimen chemotherapy.Methods We retrospectively analyzed the clinical materials from 20 patients with HER2-positive advanced gastric cancer who were treated with trastuzumab combination with modified DCF regimen chemotherapy during January 2011 and December 2012,and summarized the key point of nursing.Results The rate of disease control was 80％ in 20 patients after the combined treatment.The main adverse events were 12 cases of neutropenia,7 cases of nausea/vomiting,5 cases of cardiac toxicity,3 cases of hyperglycemia,3 cases of hyponatremia,3cases of liver function damage and 2 cases of stomatitis,and the degree of adverse reactions was grade Ⅰ-Ⅲ.The main adverse events were relieved after the corresponding treatment and nursing,and have obtained the satisfactory curative effect.Conclusions Application of trastuzumab combination with modified DCF regimen in patients with HER2-positive advanced gastric cancer was novel,effective treatment method.Taking corresponding nursing measures can ameliorate and reduce adverse reactions and improve the life quality of patients during the treatment. Key words: Gastric cancer; Chemotherapy; Nursing; Trsatuzumab; Modified DCF regimen chemotherapy